Sihuan Pharmaceutical (00460) rose 10%. As of press release, it was up 10% to HK$0.55, with a turnover of HK$3.9036 million.
The Zhitong Finance App learned that Sihuan Pharmaceutical (00460) rose 10%. As of press release, it had risen 10% to HK$0.55, with a turnover of HK$3.9036 million.
According to the news, Sihuan Pharmaceutical previously announced that the sodium-glucose transporter 2 inhibitor (SGLT-2 inhibitor) developed by Huisheng Biology, a non-wholly-owned subsidiary of the group, and proline gagliflozin tablets (trade name: Huiyoujing, “gagliflozin”) were approved for marketing by the State Drug Administration to treat type 2 diabetes. Clinical phase III study data showed that gagliflozin not only had significant hypoglycemic efficacy (the decrease in glycated hemoglobin was up to 1.4% from the baseline); it also had multiple benefits such as lowering blood pressure, weight loss, and improving blood lipids. The risk of hypoglycemia was low, and overall safety was good.
Additionally, Novo Nordisk announced that it will spend 11 billion US dollars to acquire three filling plants to expand production of diet pills. Novo Nordisk's CEO said the new plant “will enable us to provide services to more people with diabetes and obesity in the future.” Fangzheng Securities believes that with the rapid expansion of the weight loss market, simeglutide is expected to further open up the global market. We continue to be optimistic about the potential application of GLP-1 therapy to health problems, and the domestic industrial chain will expand more rapidly in the future.